市场调查报告书
商品编码
1368659
下游加工市场规模 - 按技术、按产品(色谱柱、树脂、过滤器)、按应用(单株抗体、疫苗)、最终用户和预测,2023-2032 年Downstream Processing Market Size - By Technique, By Product (Chromatography Columns, Resins, Filters), By Application (Monoclonal Antibody, Vaccine), End-user & Forecast, 2023-2032 |
由于慢性病盛行率不断上升,加上人口老化不断加剧,下游加工市场规模预计2023年至2032年复合年增长率为10.5%。根据美国国立卫生研究院的数据,到2050年,99.5%的50岁以上人口将患有至少一种慢性病。 2020年,超过7,100万人患有至少一种慢性病,预计到2050年这数字将超过1.42亿人。
随着越来越多地采用单株抗体和重组蛋白来治疗这些慢性疾病,对生物製药产品的需求持续激增。这一因素以及下游加工方法的技术发展和创新正在推动市场成长轨迹。
下游加工市场根据技术、产品、应用、最终用户和地区划分。
预计从 2023 年到 2032 年,固液分离领域的复合年增长率将达到 11.2%。离心、过滤和色谱等技术因其能够有效地从复杂混合物中分离生物分子而受到重视。这些技术的不断改进增强了纯化工艺,从而生产出高品质的生物製药产品。创新分离技术的整合降低了生产成本,使这些技术越来越适用于各种下游加工应用。
由于采用了先进的过滤技术,包括微滤、超滤和奈米滤,过滤器领域预计 2023 年和 2032 年复合年增长率将达到 11.6%。这些过程最大限度地降低了污染风险。开发能够去除杂质并保持精细生物分子完整性的高性能过滤器对于满足严格的监管要求并确保生物製药行业的产品安全性和有效性至关重要。
受医疗保健基础设施投资增加、生物製药製造业不断增长以及研发活动不断增加等因素的推动,亚太地区下游加工市场规模预计在 2023 年至 2032 年期间复合年增长率将接近 11%。中国、印度和日本等国家的生物技术和製药产业正在取得巨大进步,导致对下游加工解决方案的需求激增。庞大的患者群体和对个人化医疗的日益关注进一步推动了该地区的市场成长。
Downstream processing market size is expected to 10.5% CAGR from 2023 to 2032 owing to the increasing prevalence of chronic diseases, coupled with a growing aging population. According to the National Institutes of Health, by 2050, 99.5% of the population above the age of 50 years or older will have at least one chronic disease. In 2020, more than 71 million people had at least one chronic disease which is expected to reach more than 142 million by 2050.
The demand for biopharmaceutical products continues to surge with the rising adoption of monoclonal antibodies and recombinant proteins for treating these chronic diseases. This factor, along with the technological developments and innovations in downstream processing methodologies are contributing to the market growth trajectory.
The downstream processing market is divided based on technique, product, application, end-user, and region.
The solid-liquid separation segment is predicted to record 11.2% CAGR from 2023 to 2032. Techniques like centrifugation, filtration, and chromatography have gained prominence due to their ability to efficiently separate biomolecules from complex mixtures. Continuous improvements in these techniques have led to enhanced purification processes, resulting in the production of high-quality biopharmaceutical products. The integration of innovative separation technologies has reduced production costs, making these techniques increasingly viable for various downstream processing applications.
The filters segment is anticipated to observe 11.6% CAGR during 2023 and 2032 owing to the adoption of advanced filtration technologies, including microfiltration, ultrafiltration, and nanofiltration. These processes have minimized the risk of contamination. The development of high-performance filters capable of removing impurities and preserving the integrity of delicate biomolecules has become crucial in meeting stringent regulatory requirements and ensuring product safety and efficacy in the biopharmaceutical industry.
Asia Pacific downstream processing market size is expected to observe nearly 11% CAGR between 2023 and 2032, driven by factors such as increasing investments in healthcare infrastructure, a growing biopharmaceutical manufacturing sector, and rising R&D activities. Countries like China, India, and Japan are witnessing substantial advancements in biotechnology and pharmaceutical industries, leading to a surge in demand for downstream processing solutions. The presence of a large patient pool and the escalating focus on personalized medicine are further propelling the market growth in the region.